LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test

/PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B...

Related Keywords

United States ,United Kingdom ,London ,City Of ,Ron Zwanziger ,Colleen Mcmillen ,Exchange Commission ,Department Of Health ,Human Services ,National Institutes Of Health ,Drug Administration ,National Institute Of Biomedical Imaging ,Emergency Use Authorization ,Lumiradx Point ,Care Platform ,Lumiradx Chief Executive Officer ,Rapid Acceleration ,National Institute ,Biomedical Imaging ,National Institutes ,Securities Litigation Reform Act ,Proxy Statement ,Lumiradx Limited ,